A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
- Registration Number
- NCT01702571
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2185
- HER2-positive disease determined locally
- Histologically or cytologically confirmed invasive breast cancer
- Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced or metastatic setting must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent
- Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy
- Measurable and/or non-measurable disease
- Left ventricular ejection fraction (LVEF) >/=50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
- Adequate organ function
- Use of highly effective contraception as defined by the protocol
- History of treatment with trastuzumab emtansine
- Prior enrollment into a clinical study containing trastuzumab emtansine regardless of having received trastuzumab emtansine or not
- Peripheral neuropathy of Grade >/= 3 per National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 4.0
- History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer
- History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to first study treatment except hormone therapy, which can be given up to 7 days prior to first study treatment; recovery of treatment-related toxicity consistent with other eligibility criteria
- History of exposure to cumulative doses of anthracyclines
- History of radiation therapy within 14 days of first study treatment. The participant must have recovered from any resulting acute toxicity (to Grade </=1) prior to first study treatment.
- Metastatic central nervous system (CNS) disease only
- Brain metastases which are symptomatic
- History of a decrease in LVEF to less than (<) 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment
- History of symptomatic CHF (New York Heart Association [NYHA] Classes II-IV) or serious cardiac arrhythmia requiring treatment
- History of myocardial infarction or unstable angina within 6 months of first study treatment
- Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy
- Current severe, uncontrolled systemic disease (clinically significant cardiovascular, pulmonary, or metabolic disease)
- Pregnancy or lactation
- Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
- History of intolerance (such as Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any component of the product
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Trastuzumab Emtansine (All Participants) Trastuzumab Emtansine This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression. Trastuzumab Emtansine (Asian Participants) Trastuzumab Emtansine This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
- Primary Outcome Measures
Name Time Method Percentage of Participants With Adverse Events of Primary Interest (AEPIs) Baseline up to approximately 7 years The AEPIs in this study were defined as the following: adverse events (AEs) Grade \>/= 3, specifically, hepatic events, allergic reactions, thrombocytopenia and hemorrhage events, all Grade \>/= 3 AEs related to trastuzumab emtansine and pneumonitis events of all grades.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Specific AEPIs Baseline up to approximately 7 years The AEPIs in this study were defined as the following: adverse events (AEs) Grade \>/= 3, specifically, hepatic events, allergic reactions, thrombocytopenia and hemorrhage events, all Grade \>/= 3 AEs related to trastuzumab emtansine and pneumonitis events of all grades.
Progression-Free Survival According to Response Evaluation for Solid Tumors (RECIST) Version (v) 1.1 As Per Investigator Assessment Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) Progression free survival is defined as the time (in months) between the date of first dose and the date of disease progression or death from any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm).
Overall Survival Baseline until death (up to approximately 7 years) Overall survival is defined as time to death, which is the time from the date of dosing until the date of death, regardless of the cause of death.
Number of Hospital Visits Baseline up to approximately 7 years The number of hospital visits were recorded to evaluate the resoruce expenditures while participants were on study treatment.
Time to Response According to RECIST v 1.1 Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) Time to Response is defined as the time from first dose to first documentation of confirmed PR or CR (whichever occurs first). CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.
Type of Hospital Visits Baseline up to approximately 7 years The type of hospital visits (intensive care unit (ICU) versus other) were recorded to evaluate the resoruce expenditures while participants were on study treatment. The number of participants with at least one ICU visit are based on the number of participants with at least one hospital visit, in each group.
Percentage of Participants With Adverse Events of Special Interest (AESIs) Baseline up to approximately 7 years AESIs included: 1) Potential drug-induced liver injury, which included any potential case of drug-induced liver injury as, assessed by laboratory criteria for Hy's law (AST and/or ALT elevations that were \>3 × ULN, Concurrent elevation of total bilirubin \>2 × ULN (or clinical jaundice if total bilirubin measures were not available), except in participants with documented Gilbert's syndrome. Those with Gilbert's syndrome, elevation of direct bilirubin \>2 × ULN was used instead. 2) Suspected transmission of an infectious agent by study drug was defined as any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic. A transmission of an infectious agent suspected from clinical symptoms or laboratory findings indicating an infection in a participant exposed to a medicinal product.
Percentage of Participants With Best Overall Response (Complete Response [CR] or Partial Response [PR]) According to RECIST v 1.1 As Per Investigator Assessment Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) Best Overall Response reported here is the Best confirmed Overall Response. To be assigned a status of PR or CR, i.e., to be a responder, changes in tumor measurements had to be confirmed by repeat assessments that had to be performed no less than 4 weeks after the criteria for response were first met, i.e., participants needed to have two consecutive assessments of PR or CR. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.
Percentage of Participants With Clinical Benefit (CR or PR or Stable Disease [SD]) According to RECIST v 1.1 Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) Clinical Benefit was defined as CR plus PR plus SD. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD: neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD.
Duration of Response (DOR) According to RECIST v 1.1 Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) DOR is defined as the period from the date of initial confirmed PR or CR (whichever occurs first) until the date of PD or death from any cause. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/= 5 millimeters (mm).
Trial Locations
- Locations (300)
Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research
🇦🇺North Sydney, New South Wales, Australia
CEMIC
🇦🇷Buenos Aires, Argentina
CHU Sart-Tilman
🇧🇪Liège, Belgium
BC Cancer - Surrey
🇨🇦Surrey, British Columbia, Canada
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
Hospital Metropolitano de Santiago
🇩🇴Santiago, Dominican Republic
Clinica Alcivar, torre 1;Private office
🇪🇨Guayaquil, Ecuador
KYS Sadesairaala; Syopatautien poliklinikka
🇫🇮Kuopio, Finland
North Estonia Medical Centre Foundation; Oncology Center
🇪🇪Tallinn, Estonia
Turku Uni Central Hospital; Oncology Clinics
🇫🇮Turku, Finland
Papageorgiou General Hospital; Medical Oncology
🇬🇷Thessaloniki, Greece
Ospedale Civile; Oncologia Medica
🇮🇹Camposampiero, Veneto, Italy
Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia
🇪🇸Las Palmas de Gran Canaria, LAS Palmas, Spain
Centro Oncologico America
🇵🇦Panama, Panama
Fakultna nemocnica Trencín; Onkologicke odd.
🇸🇰Trencin, Slovakia
Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia
🇪🇸Las Palmas de Gran Canaria, LAS Palmas, Spain
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
🇪🇸Badalona, Barcelona, Spain
Clinique Tivoli; Chimiotherapie Radiotherapie
🇫🇷Bordeaux, France
Hopital Morvan; Oncologie - Radiotherapie
🇫🇷Brest, France
Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie
🇫🇷Grenoble, France
Centre Catalan D' Oncologie
🇫🇷Perpignan, France
Polyclinique De Courlancy; Centre Radiotherapie Oncologie
🇫🇷Reims, France
Institut für Versorgungsforschung in der Onkologie GbR Koblenz
🇩🇪Koblenz, Germany
Klinikum Leverkusen; Med. Klinik III / Onkologie
🇩🇪Leverkusen, Germany
Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe
🇩🇪Münster, Germany
Universitaetsfrauenklinik; Und Poliklinik Am Klinikum
🇩🇪Rostock, Germany
University Hospital of Patras Medical Oncology
🇬🇷Patras, Greece
Cancer Hospital Chinese Academy of Medical Sciences.
🇨🇳Beijing, China
Ospedale Busonera; Oncologia Medica
🇮🇹Padova, Veneto, Italy
Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia
🇪🇸Girona, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology
🇹🇷Istanbul, Turkey
Kocaeli University Faculty of Medicine; Medical oncology
🇹🇷Izmit, Turkey
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
🇮🇹Perugia, Umbria, Italy
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Azienda Ospedaliera San Giuseppe Moscati
🇮🇹Avellino, Campania, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
🇮🇹Napoli, Campania, Italy
Divisione Onc Med dell'Azienda
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Ospedale Bellaria; U.O. Oncologia Medica
🇮🇹Bologna, Emilia-Romagna, Italy
Az. Osp. Ospedale Civile; U.O. Di Oncologia Medica Ed Ematologia
🇮🇹Piacenza, Emilia-Romagna, Italy
ASST DI CREMONA; Unità di Patologia Mammaria Senologia e Breast Unit
🇮🇹Cremona, Lombardia, Italy
A.O.U Careggi
🇮🇹Florence, Toscana, Italy
Centre Hartmann
🇫🇷Levallois Perret, France
Centro Oncologico Riojano Integral (CORI)
🇦🇷La Rioja, Argentina
Hospital Privado De Comunidad; General Practice
🇦🇷Mar Del Plata, Argentina
Calvary Mater Newcastle; Medical Oncology
🇦🇺Waratah, New South Wales, Australia
Haematology & Oncology Clinics of Australia Research Centre
🇦🇺South Brisbane, Queensland, Australia
Westmead Hospital; Medical Oncology and Pallative Care
🇦🇺Westmead, New South Wales, Australia
Peter MacCallum Cancer Centre; Medical Oncology
🇦🇺Melbourne, Victoria, Australia
Sunshine Hospital; Oncology Research
🇦🇺St Albans, Victoria, Australia
Ashford Cancer Center Research
🇦🇺Kurralta Park, South Australia, Australia
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
🇦🇹Salzburg, Austria
Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
🇦🇹Wien, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
🇦🇹Wien, Austria
Institut Jules Bordet
🇧🇪Anderlecht, Belgium
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
UZ Brussel
🇧🇪Brussel, Belgium
GHdC Site Notre Dame
🇧🇪Charleroi, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
UZ Gent
🇧🇪Gent, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Clinique Ste-Elisabeth
🇧🇪Namur, Belgium
*X*Instituto Nacional do Cancer - INCA
🇧🇷Rio de Janeiro, RJ, Brazil
Sint Augustinus Wilrijk, Apotheek
🇧🇪Wilrijk, Belgium
Centro de Pesquisas Oncologicas - CEPON
🇧🇷Florianopolis, SC, Brazil
Hospital Sao Lucas - PUCRS
🇧🇷Porto Alegre, RS, Brazil
Hospital Sirio Libanes; Centro de Oncologia
🇧🇷Sao Paulo, SP, Brazil
MHAT Serdika; Department of medical oncology
🇧🇬Sofia, Bulgaria
SHATO - Sofia
🇧🇬Sofia, Bulgaria
Hopital Maisonneuve- Rosemont; Oncology
🇨🇦Montreal, Quebec, Canada
Mcgill University - Royal Victoria Hospital; Oncology
🇨🇦Montreal, Quebec, Canada
London Regional Cancer Centre
🇨🇦London, Ontario, Canada
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials
🇨🇦Barrie, Ontario, Canada
Southlake Regional Health Center; Community Care Clinic / Oncology
🇨🇦Newmarket, Ontario, Canada
St. Michael'S Hospital
🇨🇦Toronto, Ontario, Canada
District Oncology Dispensary Wit Stationary
🇧🇬Varna, Bulgaria
SHATOD - Sofia
🇧🇬Sofia, Bulgaria
Dr. H. Bliss Murphy Cancer Centre; Oncology
🇨🇦St. John's, Newfoundland and Labrador, Canada
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Chinese PLA General Hospital
🇨🇳Beijing, China
Sun Yet-sen University Cancer Center
🇨🇳Guangzhou, China
Sun Yat-sen Memorial Hospital
🇨🇳Guangzhou, China
Jiangsu Cancer Hospital
🇨🇳Nanjing City, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai City, China
Clinical Hospital Centre Zagreb
🇭🇷Zagreb, Croatia
Tianjin Cancer Hospital
🇨🇳Tianjin, China
Zhejiang Cancer Hospital
🇨🇳Zhejiang, China
Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd.
🇩🇰Aalborg, Denmark
Herlev Hospital; Afdeling for Kræftbehandling
🇩🇰Herlev, Denmark
Nordsjællands Hospital, Hillerød, Onkologisk Afdeling
🇩🇰Hillerod, Denmark
Odense Universitetshospital, Onkologisk Afdeling R
🇩🇰Odense C, Denmark
Rigshospitalet; Onkologisk Klinik
🇩🇰København Ø, Denmark
Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium
🇩🇰Roskilde, Denmark
Vejle Sygehus; Onkologisk Afdeling
🇩🇰Vejle, Denmark
Hospital Solca Portoviejo; Oncologia
🇪🇨Portoviejo, Ecuador
Helsingin yliopistollinen keskussairaala
🇫🇮Helsinki, Finland
Clinique De L Europe; Radiotherapie Chimiotherapie
🇫🇷Amiens, France
Tampere University Hospital; Dept of Oncology
🇫🇮Tampere, Finland
Hopital Jean Minjoz - CHU de Besançon
🇫🇷Besançon, France
Institut Sainte Catherine
🇫🇷Avignon, France
Institut Bergonie; Oncologie
🇫🇷Bordeaux, France
Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
🇫🇷Bordeaux, France
ICO Paul Papin; Oncologie Medicale.
🇫🇷Angers, France
Centre Jean Perrin; Oncologie
🇫🇷Clermont Ferrand, France
Cli De La Porte De Saint Cloud; Hop De Jour De Chimiotherapie
🇫🇷Boulogne-billancourt, France
Centre Francois Baclesse; Radiotherapie
🇫🇷Caen, France
Centre Georges Francois Leclerc; Oncologie 3
🇫🇷Dijon, France
Centre Oscar Lambret; Senologie
🇫🇷Lille, France
Clinique Chenieux; Oncology
🇫🇷Limoges, France
Ch Bretagne Sud Site Scorff; Oncologie Medicale
🇫🇷Lorient, France
Centre Leon Berard
🇫🇷Lyon, France
Institut Paoli Calmettes; Oncologie Medicale
🇫🇷Marseille, France
Hopital Layne; Medecine Ambulatoire
🇫🇷Mont-de-marsan, France
Centre Val Aurelle Paul Lamarque; Recherche Clinique
🇫🇷Montpellier, France
Centre Antoine Lacassagne; Hopital De Jour A2
🇫🇷Nice, France
Institut Curie; Oncologie Medicale
🇫🇷Paris, France
HOPITAL TENON; Cancerologie Medicale
🇫🇷Paris, France
Polyclinique Francheville; Med Chimiotherapie Radiotherapie
🇫🇷Perigueux, France
Institut Jean Godinot; Oncologie Medicale
🇫🇷Reims CEDEX, France
Clinique Armoricaine Radiologie; Hopital de Jour
🇫🇷Plerin, France
Pole Regional De Cancerologie
🇫🇷Poitiers, France
Centre Eugene Marquis; Unite Huguenin
🇫🇷Rennes, France
Centre Henri Becquerel; Oncologie Medicale
🇫🇷Rouen, France
Ico Rene Gauducheau; Oncologie
🇫🇷Saint Herblain, France
Institut Claudius Regaud; Departement Oncologie Medicale
🇫🇷Toulouse, France
Centre Rene Huguenin; CONSULT SPECIALISEES
🇫🇷St Cloud, France
Centre Paul Strauss; Oncologie Medicale
🇫🇷Strasbourg, France
Clinique Pasteur; Oncologie Medicale
🇫🇷Toulouse, France
Centre Henry S Kaplan - CHU Bretonneau ; service oncologie
🇫🇷Tours, France
Centre Alexis Vautrin; Oncologie Medicale
🇫🇷Vandoeuvre-les-nancy, France
Praxis Dres. Schilling & Till
🇩🇪Berlin, Germany
Institut Gustave Roussy; Pathologie Mammaire
🇫🇷Villejuif, France
Hämatologisch-onkologische Praxis Dr. med. - Heinrich, - Bangerter
🇩🇪Augsburg, Germany
Dres. Joerg Weniger, Annette Bittrich und Berit Schuetze
🇩🇪Erfurt, Germany
Schwerpunktpraxis Onkologie/Hämatologie Dr. Dirk Pott, Dr. Christian Tirier und Carla Verena u.w.
🇩🇪Bottrop, Germany
Onkozentrum Dres. Göhler
🇩🇪Dresden, Germany
Universitätsklinikum Erlangen; Frauenklinik
🇩🇪Erlangen, Germany
HOPA MVZ GmbH
🇩🇪Hamburg, Germany
OncoResearch Lerchenfeld GmbH
🇩🇪Hamburg, Germany
Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie
🇩🇪Hannover, Germany
Klinikum der Universität München; Campus Großhadern; Klinik und Poliklinik für Frauenheilkunde
🇩🇪Muenchen, Germany
Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe
🇩🇪Offenbach, Germany
Universitätsklinik Tübingen; Frauenklinik
🇩🇪Tübingen, Germany
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Klinik für Gynäkologie und gynäkologische Onkologie
🇩🇪Wiesbaden, Germany
Praxis für Hämatologie und Onkologie
🇩🇪Porta Westfalica, Germany
University General Hospital of Heraklion
🇬🇷Crete, Greece
Uni Hospital of Ioannina; Oncology Dept.
🇬🇷Ioannina, Greece
Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker
🇩🇪Würzburg, Germany
Centro Oncológico Sixtino / Centro Oncológico SA
🇬🇹Guatemala, Guatemala
Ogyi, Orszagos Gyogyszereszeti Intezet
🇭🇺Budapest, Hungary
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
🇭🇺Budapest, Hungary
Szent Imre Hospital; Dept. of Oncology
🇭🇺Budapest, Hungary
Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely
🇭🇺Budapest, Hungary
Cipto Mangunkusumo General Hospital; Hematology & Oncology
🇮🇩Jakarta, Indonesia
Kaposi Mor County Hospital; Dept. of Oncology
🇭🇺Kaposvar, Hungary
Dharmais National Cancer Center
🇮🇩Jakarta, Indonesia
Landspitali University Hospital, Department of Medical Oncology
🇮🇸Reykjavik, Iceland
MRCCC Siloam Semanggi Hospital
🇮🇩Jakarta, Indonesia
Cork Uni Hospital; Oncology Dept
🇮🇪Cork, Ireland
St Vincent'S Uni Hospital; Medical Oncology
🇮🇪Dublin, Ireland
Mater Misericordiae Uni Hospital; Oncology
🇮🇪Dublin, Ireland
University Hospital Limerick - Oncology
🇮🇪Limerick, Ireland
A.O.U. Policlinico di Modena
🇮🇹Modena, Emilia-Romagna, Italy
Università degli Studi Federico II; Clinica di Oncologia Medica
🇮🇹Napoli, Campania, Italy
RCCS - Centro di Riferimento; Oncologia Medica B
🇮🇹Aviano (PN), Friuli-Venezia Giulia, Italy
Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche
🇮🇹Roma, Lazio, Italy
Ospedale S.S. Trinità Nuovo; Divisione Oncologia
🇮🇹Sora, Lazio, Italy
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
🇮🇹Genova, Liguria, Italy
ASST DI LECCO; Oncologia Medica
🇮🇹Lecco, Lombardia, Italy
Ospedale San Raffaele; Medical Oncology
🇮🇹Milano, Lombardia, Italy
Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica
🇮🇹Pavia, Lombardia, Italy
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
🇮🇹Milano, Lombardia, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
🇮🇹Candiolo, Piemonte, Italy
Casa di Cura Multimedica S.p.A.; Dipartimento Oncologico
🇮🇹Sesto San Giovanni (MI), Lombardia, Italy
Ospedale Maggiore Della Carita; Oncologia Medica
🇮🇹Novara, Piemonte, Italy
A.O. Città della Salute e della Scienza - Presidio Molinette; divisione oncologia medica
🇮🇹Torino, Piemonte, Italy
Ospedale Antonio Perrino; Oncologia Medica
🇮🇹Brindisi, Puglia, Italy
Ospedale Vito Fazzi; Div. Oncoematologia
🇮🇹Lecce, Puglia, Italy
Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica
🇮🇹Catania, Sicilia, Italy
Azienda usl 5 Di Pisa-Ospedale Di Pontedera;U.O. Oncologia
🇮🇹Pontedera, Toscana, Italy
Ospedale Misericordia E Dolce; Oncologia Medica
🇮🇹Prato, Toscana, Italy
A.O.U.I. VERONA-OSPEDALE BORGO TRENTO; ONCOLODIA MEDICA-d.O.
🇮🇹Verona, Veneto, Italy
Kyungpook National University Medical Center
🇰🇷Daegu, Korea, Republic of
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
CHL Hopital Municipal; Oncology
🇱🇺Luxembourg, Luxembourg
Korea University Anam Hospital; Oncology Haemotology
🇰🇷Seoul, Korea, Republic of
Gachon Medical School Gil Medical Center; Medical Oncology
🇰🇷Incheon, Korea, Republic of
Yonsei University Severance Hospital; Medical Oncology
🇰🇷Seoul, Korea, Republic of
Hospital General de México
🇲🇽Mexico City, Mexico CITY (federal District), Mexico
Medica Sur Centro Oncologico Integral
🇲🇽D.f., Mexico
Hospital Hmg Coyoacan
🇲🇽DF, Mexico
CENTRO MÉDICO NACIONAL SIGLO XXI; Hospital de Especialidades Oncología
🇲🇽Mexico City, Mexico
Inst. Nacional de Cancerologia; Investigacion Clinica
🇲🇽Mexico City, Mexico
Oslo Universitetssykehus HF; Ullevål sykehus
🇳🇴Oslo, Norway
Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán
🇲🇽Mexico City, Mexico
Ziekenhuisgroep Twente, Hengelo
🇳🇱Hengelo, Netherlands
Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde
🇳🇱Amsterdam, Netherlands
Amphia Ziekenhuis
🇳🇱Breda, Netherlands
MC Haaglanden; Oncologie
🇳🇱Den Haag, Netherlands
Deventer Ziekenhuis; Interne Geneeskunde
🇳🇱Deventer, Netherlands
Spaarne Ziekenhuis; Inwendige Geneeskunde
🇳🇱Hoofddorp, Netherlands
Medisch Centrum Leeuwarden; Interne
🇳🇱Leeuwarden, Netherlands
Twee Steden Ziekenhuis - Locatie Tilburg; Interne Geneesekunde
🇳🇱Tilburg, Netherlands
Orbis Medisch Centrum; Inwendige Geneeskunde
🇳🇱Sittard-Geleen, Netherlands
Centro Hemato Oncologico Panama
🇵🇦Panama, Panama
Instituto;Oncologico Miraflores
🇵🇪Lima, Peru
Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej
🇵🇱Bialystok, Poland
Szpital Specjalistyczny POO im. ks. B.Markiewicza; Dzienny Oddz Chemioter i Hematologii Onkol
🇵🇱Brzozów, Poland
Clinica de Especialidades Medicas
🇵🇪Lima, Peru
Świętokrzyskie Centrum Onkologii; Dział Chemioterapii
🇵🇱Kielce, Poland
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
🇵🇱Kraków, Poland
IPO de Lisboa; Servico de Oncologia Medica
🇵🇹Lisboa, Portugal
Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii
🇵🇱Otwock, Poland
Wojewódzki Szpital Specjalistyczny Nr 3
🇵🇱Rybnik, Poland
IPO do Porto; Servico de Oncologia Medica
🇵🇹Porto, Portugal
Hospital da Luz; Departamento de Oncologia Medica
🇵🇹Lisboa, Portugal
Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A
🇸🇰Bratislava, Slovakia
Institute of Oncology Ljubljana
🇸🇮Ljubljana, Slovenia
Hospital General Universitario de Elche; Servicio de Oncologia
🇪🇸Elche, Alicante, Spain
Hospital Univ. Central de Asturias; Servicio de Oncologia
🇪🇸Oviedo, Asturias, Spain
Hospital General de Elda; Servicio de Oncologia
🇪🇸Elda, Alicante, Spain
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
🇪🇸Sabadell, Barcelona, Spain
Hospital de Jerez de la Frontera; Servicio de Oncologia
🇪🇸Jerez de La Frontera, Cadiz, Spain
Hospital de Donostia; Servicio de Oncologia Medica
🇪🇸San Sebastian, Guipuzcoa, Spain
Hospital Universitario Son Espases
🇪🇸Palma De Mallorca, Islas Baleares, Spain
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸Córdoba, Cordoba, Spain
Hospital Severo Ochoa; Servicio de Oncologia
🇪🇸Leganes, Madrid, Spain
Hospital Quiron de Madrid; Servicio de Oncologia
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Hospital Xeral Cíes; Servicio de Oncologia
🇪🇸Vigo, Pontevedra, Spain
Hospital San Pedro De Alcantara; Servicio de Oncologia
🇪🇸Caceres, Spain
Hospital Universitari Sant Joan de Reus; Servicio de Oncologia
🇪🇸Reus, Tarragona, Spain
Hospital General Univ. de Alicante; Servicio de Oncologia
🇪🇸Alicante, Spain
Hospital de Cruces; Servicio de Oncologia
🇪🇸Bilbao, Vizcaya, Spain
Hospital del Mar; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital Quiron Barcelona; Servicio de Oncologia
🇪🇸Barcelona, Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
🇪🇸Jaen, Spain
Hospital Universitario San Cecilio; Servicio de Oncologia
🇪🇸Granada, Spain
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
🇪🇸La Coruña, Spain
Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia
🇪🇸Lerida, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸Madrid, Spain
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
🇪🇸Madrid, Spain
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Complejo Hospitalario de Pontevedra; Servicio de Oncologia
🇪🇸Pontevedra, Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
🇪🇸Malaga, Spain
Hospital Universitario Miguel Servet; Servicio Oncologia
🇪🇸Zaragoza, Spain
Hospital General Universitario de Valencia; Servicio de oncologia
🇪🇸Valencia, Spain
Karolinska Hospital; Oncology - Radiumhemmet
🇸🇪Stockholm, Sweden
Norrlands universitetssjukhus; Onkologkliniken
🇸🇪Umeå, Sweden
Chi-Mei Medical Centre; Hematology & Oncology
🇨🇳Tainan, Taiwan
National Cheng Kung Uni Hospital; Surgery
🇨🇳Tainan, Taiwan
VETERANS GENERAL HOSPITAL; Department of General Surgery
🇨🇳Taipei, Taiwan
Department of Surgery, King Chulalongkorn Memorial Hospital
🇹🇭Bangkok, Thailand
Pramongkutklao Hospital; Medicine - Medical Oncology Unit
🇹🇭Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial
🇹🇭Chiang Mai, Thailand
Gazi Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Ankara, Turkey
Bezmialem Vakif Univ Medical; Bezmialem Vakif Univ T
🇹🇷Istanbul, Turkey
Gaziantep University Medical Faculty, Medical Oncology Department
🇹🇷Gaziantep, Turkey
Istanbul Uni of Medicine Faculty; Oncology Dept
🇹🇷Istanbul, Turkey
Kartal Dr Lutfi Kirdar Sehir Hastanesi; Medical Oncology Department
🇹🇷Istanbul, Turkey
Marmara Uni Faculty of Medicine; Medical Oncology
🇹🇷Istanbul, Turkey
Ege Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Izmir, Turkey
Dokuz Eylul Uni ; Medical Oncology
🇹🇷Izmir, Turkey
Tawam Hospital
🇦🇪Al Ain, United Arab Emirates
Aberdeen Royal Infirmary
🇬🇧Aberdeen, United Kingdom
University Hospital coventry; Oncology Department
🇬🇧Coventry, United Kingdom
University Hospital Birmingham Queen Elizabeth Hospital
🇬🇧Birmingham, United Kingdom
Kent & Canterbury Hospital
🇬🇧Canterbury, United Kingdom
Eastborne District General Hospital
🇬🇧Eastbourne, United Kingdom
Western General Hospital; Clinical Oncology
🇬🇧Edinburgh, United Kingdom
St Margaret'S Hospital; Breast Unit
🇬🇧Epping, United Kingdom
Royal Devon & Exeter Hospital; Oncology Centre
🇬🇧Exeter, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Diana Princess of Wales Hosp.
🇬🇧Grimsby, United Kingdom
Ipswich Hospital; Oncology Pharmacy
🇬🇧Ipswich, United Kingdom
Castle Hill Hospital; The Queen's Centre for Oncology & Haematology
🇬🇧Hull, United Kingdom
Huddersfield Royal Infirmary
🇬🇧Huddersfield, United Kingdom
Guys & St Thomas Hospital; Department of Oncology
🇬🇧London, United Kingdom
Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust
🇬🇧Lancaster, United Kingdom
Royal Free Hospital; Dept of Oncology
🇬🇧London, United Kingdom
St George'S Hospital; Oncology Research Office /Oncology Opd
🇬🇧London, United Kingdom
Sarah Cannon Research Institute
🇬🇧London, United Kingdom
Christie Hospital; Breast Cancer Research Office
🇬🇧Manchester, United Kingdom
Maidstone & Tonbridge Wells Hospital; Kent Oncology Center
🇬🇧Maidstone, United Kingdom
Mount Vernon Hospital
🇬🇧Middlesex, United Kingdom
Plymouth Oncology Centre; Clinical Trials Unit
🇬🇧Plymouth, United Kingdom
Queen's Hospital; Oncology
🇬🇧Romford, United Kingdom
Queen Alexandra Hospital, Portsmouth
🇬🇧Portsmouth, United Kingdom
Weston Park Hospital; Cancer Clinical Trials Centre
🇬🇧Sheffield, United Kingdom
Royal Shrewsbury Hospital
🇬🇧Shrewsbury, United Kingdom
Unidad de Mastologia y Atencion a la Mujer
🇻🇪Barcelona, Venezuela
Yeovil District Hospital; Macmillan Cancer Unit
🇬🇧Yeovil, United Kingdom
Instituto Oncológico Luis Razetti
🇻🇪Caracas, Venezuela
Singleton Hospital; Pharmacy
🇬🇧Swansea, United Kingdom
York District Hospital
🇬🇧York, United Kingdom
Instituto de Oncologia y Hematologia UCV
🇻🇪Caracas, Venezuela
Hospital Sao Jose
🇧🇷Sao Paulo, SP, Brazil
Princess Margaret Hospital; Oncology
🇭🇰Hong Kong, Hong Kong
Prince of Wales Hosp; Dept. Of Clinical Onc
🇭🇰Shatin, Hong Kong